1656 LACK OF CONSISTENT THERAPEUTIC EFFECTS OF REPEATED 200 U ONABOTULINUMTOXINA DETRUSOR INJECTIONS ON URINARY INCONTINENCE IN CHRONIC SPINAL CORD INJURED PATIENTS

Abstract

point increase from BL in I-QOL score), total volume/void, and adverse events (AEs). RESULTS: A total of 387, 336, 241, 113, and 46 patients received 1, 2, 3, 4, and 5 onabotA treatments. UI episodes/wk were consistently reduced compared to BL following repeated onabotA treatment; reductions from BL were -22.7, -23.3, -23.1, -25.3, and -31.9 for onabotA 200U and -23.8, -25.0, -23.6, -24.1, and -29.5 for onabotA 300U at Wk 6 in treatment cycles 1 through 5, respectively (P 0.001 vs BL). The proportion of pts reporting 50% reductions from BL in UI episodes and 100% reduction in UI episodes (“dry”) at Wk 6 ranged from 73-94% and 36-55%, respectively, across the 5 treatment cycles. A consistent response was also observed in the I-QOL responder rates over repeated cycles (66-93%). The most common AEs were localized urological events (urinary tract infections and urinary retention), and there was no change in the AE profile over time. CONCLUSIONS: Sustained reductions in UI episodes and improvements in QOL were observed over repeated onabotA treatments (up to 5 cycles) in pts with UI due to NDO who were inadequately managed with anticholinergics. No new safety signals were observed with repeat treatment.